The effects of ONC‐212 against CLL (CD19+/CD5+) and T‐cells (CD19−/CD5+) in PBMC fractions from CLL patients were assessed by examining the proportions of these cells before and after treatment with 2 μM ONC‐212 for 48 hours. This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.